NOVARTIS CAPITAL P Profile

66989HAP3   95.72  3.76  3.78%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Default

Less than 41

 
High
 
Low
Below Average
NOVARTIS is trading at 95.72 as of the 17th of December 2024, a 3.78% down since the beginning of the trading day. The bond's open price was 99.48. NOVARTIS has about a 41 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Ratings for NOVARTIS CAPITAL P are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 21st of April 2024 and ending today, the 17th of December 2024. Click here to learn more.

Moving against NOVARTIS Bond

  0.54KO Coca Cola Fiscal Year End 11th of February 2025 PairCorr
  0.47PFE Pfizer Inc Aggressive PushPairCorr

NOVARTIS Bond Highlights

Business ConcentrationNOVARTIS CAPITAL P Corporate Bond, Financial, Financial Services (View all Sectors)
NOVARTIS CAPITAL P (66989HAP3) is traded in USA.

NOVARTIS CAPITAL P Risk Profiles

NOVARTIS Against Markets

Be your own money manager

Our tools can tell you how much better you can do entering a position in NOVARTIS without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Sectors Now

   

Sectors

List of equity sectors categorizing publicly traded companies based on their primary business activities
All  Next Launch Module

Other Information on Investing in NOVARTIS Bond

NOVARTIS financial ratios help investors to determine whether NOVARTIS Bond is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in NOVARTIS with respect to the benefits of owning NOVARTIS security.